TOKYO -- U.S. drugmaker Eli Lilly has released its Zepbound obesity medication in Japan, targeting the millions said to suffer from the "hidden" scourge of buildups of visceral fat.
Pharmaceuticals
Eli Lilly releases Zepbound obesity drug in Japan, targeting 'hidden' fat
Pharmaceutical company eyes 18m potential patients and sales of $224m at peak
Zepbound works in the same way as hormones in the body that promote fat metabolism and suppress appetite. © Reuters
Read Next
Latest on Pharmaceuticals
